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Abstract 
Background: Fractional flow reserve (FFR) is a widely used tool for the identification of ischaemia-generating 
stenoses and to guide decisions on coronary revascularisation. However, the safety of FFR-based decisions in high-
risk subsets, such as patients with Diabetes Mellitus (DM) or vulnerable stenoses presenting thin-cap fibro-atheroma 
(TCFA), is unknown. This study will examine the impact of optical coherence tomography (OCT) plaque morphologi-
cal assessment and the identification of TCFA, in combination with FFR to better predict clinical outcomes in DM 
patients.
Methods: COMBINE (OCT–FFR) is a prospective, multi-centre study investigating the natural history of DM patients 
with ≥1 angiographically intermediate target lesion in three subgroups of patients; patients with FFR negative lesions 
without TCFA (group A) and patients with FFR negative lesions with TCFA (group B) as detected by OCT and to com-
pare these two groups with each other, as well as to a third group with FFR-positive, PCI-treated intermediate lesions 
(group C). The study hypothesis is that DM patients with TCFA (group B) have a worse outcome than those without 
TCFA (group A) and also when compared to those patients with lesions FFR ≤0.80 who underwent complete revascu-
larisation. The primary endpoint is the incidence of target lesion major adverse cardiac events (MACE); a composite of 
cardiac death, myocardial infarction or rehospitalisation for unstable/progressive angina in group B vs. group A.
Conclusion: COMBINE (OCT–FFR) is the first prospective study to examine whether the addition of OCT plaque mor-
phological evaluation to FFR haemodynamic assessment of intermediate lesions in DM patients will better predict 
MACE and possibly lead to new revascularisation strategies.
Trial Registration Netherlands Trial Register: NTR5376
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Background
Diabetes Mellitus (DM) is associated with more rap-
idly progressive coronary atherosclerosis and increased 
mortality compared to non-diabetic patients [1, 2]. Frac-
tional Flow Reserve (FFR) is a pressure-derived intra-
coronary functional index currently recommended in 
clinical practice guidelines for stenosis assessment in 
the absence of objective evidence of myocardial ischae-
mia [3]. Previous studies have shown that FFR-negative 
lesions (FFR > 0.80) can be safely treated medically, while 
FFR-positive lesions (FFR ≤ 0.80) benefit from revascu-
larisation [4, 5]. However, in the majority of the FFR trials 
performed to date, the percentage of DM patients is low 
[4–6].
More recently, several studies have suggested that 
FFR-based revascularisation may not be associated with 
the same reduction in adverse cardiac events as seen 
in non-DM patients [7–10], even when the presence of 
microvascular disease, which might imply ischaemia of 
non-obstructive origin, is taken into consideration [10]. 
These findings could be explained by the fact that, in 
patients with DM, adverse cardiac events after ischae-
mia-driven revascularisation may be related to the pres-
ence of more active atherosclerotic disease, resulting in 
subsequent acute coronary events or obstructive disease 
progression, rather than to ischaemic burden at the time 
of revascularisation [11, 12]. However, this hypothesis 
of more rapid atherosclerosis progression in high risk 
plaque, is as yet only postulated.
The PROSPECT study demonstrated an ~12 % 3-year 
rate of future unanticipated major adverse cardiovascu-
lar events (MACE) in non-culprit lesions (NCL) [13]. 
Furthermore, insulin dependent DM was identified as 
an independent predictor of NCL MACE, in addition to 
the presence of thin-cap fibroatheroma (TCFA), minimal 
lumen area (MLA) ≤4 mm2, and a plaque burden ≥70 %. 
Additionally, the rate of future NCL-related MACE was 
twice as high among patients with DM hosting at least 
one thin-cap fibroatheroma TCFA, whereas those DM 
patients without a TCFA had a more benign prognosis, 
similar to non-DM patients [14].
Although these NCL’s appeared angiographically mild, 
significant differences in plaque composition between 
those patients with versus without DM were noted [15]. 
Separately, Kato et  al. have shown that the incidence of 
TCFA in patients with DM is higher than in patients 
without DM [16]. As FFR was not measured in PROS-
PECT, whether these lesions were truly non-ischaemic is 
unknown, however given the mild angiographic severity 
(diameter stenosis; median 36.2 % IQR [31.1, 44.2]) this 
was unlikely. Nonetheless, it has been shown that these 
high risk IVUS-detected plaque features have no corre-
lation with FFR functional significance of intermediate 
coronary lesions, and so whether ischaemia is the only 
factor in the prediction of future adverse cardiac events is 
questionable [17].
Several studies using intravascular ultrasound (IVUS), 
have attempted to address the mismatch between the 
functional and anatomical significance of intermediate 
coronary lesions, however these have largely focused 
on quantitative assessments of MLA, lesion length and 
plaque burden. From these studies, it has been shown 
that only a mere moderate correlation between IVUS 
quantitative measurements and FFR exists [17–19].
Optical Coherence Tomography (OCT) is an intravas-
cular imaging modality that provides a spatial resolution 
10 times higher than IVUS [20]. Whilst OCT is superior 
to IVUS in identifying the haemodynamic significance 
of coronary stenoses, particularly in vessels  <3  mm, its 
low specificity and only modest diagnostic efficacy pre-
cludes its use as a substitute for FFR functional stenosis 
assessment [21]. However, the true benefit of OCT may 
centre upon its superior ability to detect high risk vulner-
able plaque. With the introduction of OCT, our under-
standing of plaque morphology and the mechanisms of 
plaque rupture which result in ACS have been signifi-
cantly advanced [22, 23]. A thin fibrous cap overlying a 
lipid-rich necrotic core is believed to be the substrate 
for most vulnerable plaques, and OCT is the only imag-
ing modality that currently can accurately assess fibrous 
cap thickness [24]. Multiple intravascular imaging studies 
have shown the the presence of vulnerable plaque char-
acteristics are more prevalent in DM patients compared 
to non-DM patients and in particular a greater burden of 
TCFA lesions [25–28]. Due to these characteristics, OCT 
is being frequently used to evaluate lesion morphology, 
however, the predictive value of this modality with regard 
to future MACE is not well studied.
In the COMBINE (OCT–FFR) study, we propose to 
investigate the incremental value of OCT plaque mor-
phological evaluation added to FFR haemodynamic 
assessment of intermediate lesions in DM patients in 
predicting MACE when following an ischaemia-driven 
revascularization strategy.
Study design and objectives
The COMBINE (OCT–FFR) is a prospective multi-centre, 
international study, involving centres in the Netherlands, 
Germany, Spain, Italy, Switzerland and Poland. The study 
was approved by the Institutional Review Board of each 
participating hospital. The study is registered on the Neth-
erlands Trial Registry under the identifier NTR5376 [29]. 
The primary objective of the COMBINE (OCT–FFR) 
study is to evaluate whether the presence of certain 
plaque characteristics considered to carry a high-risk 
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(such as TCFA) in lesions with an intermediate-severe 
angiographic stenosis but which are non-ischaemic 
(FFR  >  0.80) can predict future adverse cardiac events. 
For this purpose, we have selected to examine only 
patients with DM, as these patients constitute the sub-
population with the fastest progression of coronary ath-
erosclerosis and where recent evidence suggests that 
deferred revascularisation based upon FFR assessment 
may not be as safe as in non-DM patients.
The study design is illustrated in Fig. 1. The study pop-
ulation consists of all DM patients with any clinical pres-
entation who undergo FFR assessment in lesions with an 
intermediate-severe angiographic stenosis. Inclusion and 
exclusion criteria are presented in Table 1. Lesions which 
are determined as the culprit lesion in myocardial infarc-
tion will not be included, owing to the lack of evidence 
for FFR in such clinical scenarios. FFR will be performed 
according to standard protocol using the PressureWire 
Aeris™ or Certus™ wires, St. Jude Medical, St. Paul, Min-
nesota, USA. Adenosine is the preferred hyperaemic 
agent to be administered via the intravenous route at a 
recommended dose of 140  μg/kg/min to achieve maxi-
mum hyperaemia. Should intracoronary adenosine be 
administered, a dose of 40 μg for the right coronary artery 
and 80  μg for the left coronary artery is recommended. 
Once steady-state maximum hyperaemia is achieved, 
FFR is calculated as the ratio of mean distal intracoronary 
pressure measured by the pressure wire, and the mean 
arterial pressure measured through the coronary guid-
ing catheter. In all patients where FFR is performed, OCT 
assessment using the frequency domain Dragonfly™ 
OCT system, St. Jude Medical, St. Paul, Minnesota, USA 
will also take place. Patients with ≥1 lesion which does 
not undergo revascularisation based upon a FFR negative 
(>0.80) assessment will be followed clinically. Depend-
ing upon the OCT findings, patients without any TCFA 
(see Additional file  1: Appendix for definition) lesions 
will form Group A, whilst patients with  ≥1 TCFA car-
rying lesion will form Group B. Finally, patients hosting 
only FFR-positive target lesions and no other remaining 
lesions, which have undergone complete index revascu-
larisation either by PCI or CABG will form Group C. 
 DM patients that undergo angiography for any indication  
with at least 1 lesion ≥40-≤80% diameter stenosis on visual angiographic estimation 
(other than the culprit if presentation is MI) 
where FFR and OCT have been performed 




Presence of ≥1 thin cap 
Fibroatheroma 
 (TCFA) 
Group A  
Absence of thin cap 
ibroatheroma  
(NO-TCFA) 
All groups maintained on OMT 
Primary Endpoint: Target-lesion related MACE (Cardiac death, MI, 
hospitalization for ACS) at 18 months in group A vs B 
Major Secondary Endpoint: MACE at 18 months in group B vs C 
Presence of another 
FFR >0.80 target 
lesion  
Group C 
No other  target lesion 
remaining 

















Fig. 1 Study flow-chart
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Study endpoints
Primary endpoint
The per patient incidence of target lesion(s) related 
composite MACE defined as: Cardiac death, myocar-
dial infarction (MI), clinically-driven target lesion revas-
cularisation (TLR) or hospitalisation due to unstable or 
progressive angina at 18 months in the FFR-negative No-
TCFA patients (Group A) as compared to the FFR-nega-
tive TCFA patients (Group B).
Major secondary endpoints
1. The per patient incidence of the target lesion(s) 
related composite MACE: Cardiac Death, MI, clin-
ically-driven TLR or hospitalisation due to unsta-
ble or progressive angina between FFR-negative 
TCFA-positive patients (Group B) and the group 
of patients with PCI-treated FFR-positive lesions 
(Group C).
2. The per patient incidence composite MACE: Car-
diac death, MI, any clinically-driven revascularisa-
tion or hospitalisation due to unstable or progressive 
angina between FFR- negative TCFA (Group B) and 
the group of patients with PCI-treated FFR-positive 
lesions (Group C).
3. The incidence of MACE (Cardiac Death, MI, clini-
cally-driven revascularisation or hospitalisation due 
to unstable or progressive angina) in patients carrying 
any non-revascularised TCFA lesion (target or else-
where within the assessed coronary segments) com-
pared to patients without any identified TCFA lesions.
Additional secondary endpoints
 1. The incidence of the separate components of the pri-
mary endpoint at 18 months between Group A and 
Group B.
 2. The incidence of FFR positive (≤0.80) lesions in 
angiographically mild lesions (<50 % diameter of ste-
nosis) and their rate clinical outcomes at 18 months.
 3. The incidence of cardiac death, MI and and clini-
cally-driven target vessel revascularisation (TVR) at 
18 months.
 4. Clinical predictors of MACE at 18  months in 
patients with ≥ 1 FFR > 0.80 lesion.
 5. Outcome of MACE in older versus younger patients 
(cut-off 75 years) with ≥ 1 FFR > 0.80 lesion.
 6. Impact of HbA1c on the incidence of TCFA and 
MACE outcomes.
 7. The incidence of target lesion related MACE at 
18  months in the FFR- negative TCFA negative 
patients (Group A) vs. patients with PCI treated 
FFR  +  lesions with no other remaining lesions 
(Group C).
 8. The incidence of target lesion related MACE at 
18  months in FFR-negative lesions in patients with 
versus without ACS at presentation.
 9. The impact of renal insufficiency (eGFR  <  60  mls/
min) on the incidence of TCFA and MACE out-
comes.
 10. The impact of gender on the incidence of TCFA and 
MACE outcomes.
 11. The per patient incidence of the target lesion(s) 
related composite MACE defined as Cardiac Death, 
MI, clinically-driven TLR or hospitalisation due to 
unstable or progressive angina in the FFR-nega-
tive No-TCFA (Group A) and FFR- negative TCFA 
(Group B) at 3 years (if funding permits).
 12. The incidence of a composite endpoint of Cardiac 
Death, MI, clinically-driven TLR or hospitalisation 
due to unstable or progressive angina between FFR-
negative TCFA (Group B) and the group of patients 
with PCI treated FFR  +  lesions with no other 
remaining lesions (Group C) at 3  years (if funding 
permits).
 13. The impact of MI (prior or at presentation) on the 
incidence of TCFA and MACE outcomes.
 14. The impact of other OCT-detected plaque types 
(other than TCFA) on the incidence of MACE in 
Group A and Group B.
Follow‑up data collection and study management
Patient demographics and clinical data at inclusion are 
collected online in an electronic database (CRO Dia-
gram, Zwolle, The Netherlands). The first 2 patients 
included in all centres will be fully monitored to iden-
tify inconsistent data. Upon discharge and after the 
intended follow-up period of 18  months, data will 
be collected at visits at outpatient clinics or, if not 
feasible, by telephone follow-up and/or a medical 
Table 1 COMBINE OCT–FFR inclusion and exclusion criteria
DM denotes diabetes mellitus; ACS denotes acute coronary syndrome; TIMI 
denotes thrombolysis in myocardial infarction
Inclusion criteria
 Age ≥18 years
 History of DM with any indication for angiography (Stable Angina 
Pectoris or any type of ACS)
 At least ≥ 1 de novo target lesion in a native coronary segment with a 
visually estimated diameter stenosis of between ≥40 and ≤80 %
Exclusion criteria
 TIMI flow <3 in the target lesion(s)
 Target lesion reference diameter <2.0 mm
 Left Ventricular ejection fraction <30 %
 Malignancy
 Life expectancy <2 years
 Unwilling or unable to provide informed consent
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questionnaire, carried out by staff who are blinded. 
Follow-up beyond 18 months is intended, should fund-
ing permit. During visits and telephone calls, patients 
will be interviewed regarding repeat hospitalisations, 
revascularisation procedures, and myocardial infarc-
tion (MI) during follow-up. In case of death, informa-
tion will be obtained from the patient’s medical chart, 
local institution and by contact where required with 
the patient’s cardiologist/general practitioner. FFR and 
OCT core laboratory will be based at an external inde-
pendent research centre, in addition to overall trial 
coordination, data management and study monitoring 
(CRO Diagram, Zwolle, the Netherlands). An inde-
pendent clinical events committee will adjudicate all 
potential clinical endpoints.
Whilst an observational study, without randomisa-
tion, in order to confer meaning to the results derived, 
a power calculation has been made to estimate a pro-
jected number of patients that would allow observation 
of meaningful differences in MACE rates between the 
above mentioned subgroups of patients. The primary 
endpoint event rate at 18 months in the A and B group 
respectively are assumed to be 5 and 20  % respectively. 
Furthermore, we assume that 1/3 of the patients will have 
at least one lesion with a positive FFR (≤0.80) as shown 
from the major FFR trials [4, 5].
An equal distribution of patients between subgroups A 
and B is expected (50 % in each group) however the power 
calculation takes in account variations up to 20 % (i.e. an une-
qual TCFA distribution in both directions up to 30 vs. 70 %). 
Taking into account an expected loss in follow-up of 7 %, a 
total of 500 patients enrolled in the study will provide 80 % 
power to reject the null hypothesis with 5  % type I error. 
With this number of patients, it is expected that this study 
is also powered to assess its major secondary endpoint if an 
equal distribution (in groups A and B) is observed and the 
target lesion MACE rate in the group C does not exceed 7 % 
(assumption based on observations from recent novel drug-
eluting stent (DES) studies for non-complex lesions [30].
Statistical analysis
In general, statistics for continuous variables will include 
mean, median, standard deviation, minimum, maxi-
mum, and sample size for each treatment group, and 
two-sided 95 % confidence intervals of the mean differ-
ence between the treatment groups. Binary variables will 
be described with frequencies, percentages, and two-
sided 95 % confidence intervals of the difference in per-
centages between treatments using exact methods. For 
time-to-event data, Kaplan–Meier estimates at the indi-
cated time points will be displayed along with 95 % con-
fidence intervals for the difference in the estimates along 
with log rank test results. In addition, survival curves 
will be constructed for all time to event secondary end-
points using Kaplan–Meier methods. For the primary 
endpoint as for the secondary endpoint a multivariate 
regression analysis will be performed.
Present status
The COMBINE (OCT–FFR) study started enrolment 
in April 2015; and as of August 1, 2016, 148 patients 
have been included. To date 12 participating centres are 
actively enrolling, and several others are still in the start-
up process. End of the enrolment is expected in 2017.
The COMBINE (OCT–FFR) study is investigator 
driven and is supported by an unrestricted grant from St. 
Jude Medical. The authors are solely responsible for the 
design and conduct of this study, all study analyses, and 
drafting and editing of the manuscript.
Conclusion
COMBINE (OCT–FFR) is the first large prospective 
natural history study to examine whether the addition 
of OCT plaque morphological evaluation and the iden-
tification of high-risk plaque features such as TCFA, in 
combination with FFR haemodynamic assessment in DM 
patients will better predict MACE and possibly lead to 
new revascularisation strategies in a group of patients at 
high risk for future adverse cardiac events.
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